Rejuvel Bio-Sciences (NUUU) Inactive 10-Q19 Nov 142014 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2014	Nov. 19, 2014
Document And Entity Information	'	'
Entity Registrant Name	'Technology Applications International Corp	'
Entity Central Index Key	'0001481427	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	50,118,963
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2014	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets	'	'
Cash and cash equivalents	$187,880	$4,891
Inventories	97,847	70,862
Deposits	10,537	7,000
Other current assets	12,403	1,909
Total current assets	308,667	84,662
Trademarks, net	1,859	1,940
Machinery and equipment, net	33,741	19,371
Total assets	344,267	105,973
Liabilities	'	'
Accounts payable and accrued expenses	433,127	344,415
Advances from affiliate	303,490	237,480
Loan from affiliate	142,068	77,401
Notes Payable	15,000	0
Convertible debentures (net of debt discount of $0 and $75,902 respectively)	0	198,099
Derivative liability	148,285	349,940
Total current liabilities	1,041,970	1,207,335
Total liabilities	1,041,970	1,207,335
Shareholders' deficit	'	'
Preferred stock, par value, $0.001 per share, 50,000,000 shares authorized, none issued or outstanding	0	0
Common stock, par value $0.001 par value, 300,000,000 shares authorized, 50,118,493 and 117,348,000 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively.	50,118	117,348
Additional paid in capital	1,558,250	586,199
Accumulated deficit	-2,306,071	-1,804,909
Total shareholders' deficit	-697,703	-1,101,362
Total liabilities and shareholders' deficit	$344,267	$105,973

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	50,118,493	117,348,000
Common stock, shares outstanding	50,118,493	117,348,000
Discount on convertible debentures	$0	$75,902

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
Revenues	$18,353	$4,313	$63,677	$35,841
Cost of revenues	168	-1,219	9,062	6,039
Gross profit	18,185	5,532	54,615	29,802
Expenses	'	'	'	'
General and administrative	210,777	77,635	501,908	365,336
Loss From Operation	-192,592	-72,103	-447,293	-335,534
Other income (expense)	'	'	'	'
Gain (loss) on derivative valuation	629,571	-8,250	565,167	85,150
Derivative expense	-258,448	0	-525,603	0
Interest expense	-3,332	-74,050	-93,433	-231,581
Total other income (expense)	367,791	-82,300	-53,869	-146,431
Net Income (Loss)	$175,199	($154,403)	($501,162)	($481,965)
Loss per share	'	'	'	'
Basic	$0	$0	$0	$0
Diluted	$0	$0	$0	$0
Weighted average number of shares	'	'	'	'
Basic	106,187,007	117,248,000	110,001,487	117,248,000
Diluted	106,245,144	117,248,000	110,001,487	117,248,000

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities	'	'
Net loss	($501,162)	($481,965)
Adjustments to reconcile net income to net cash used in operating activities:	'	'
Gain on derivative valuation	-565,167	-85,150
Derivative expense	525,603	0
Amortization of discount on convertible debentures	75,902	214,963
Depreciation and amortization	4,046	3,060
Change in current assets and current liabilities:	'	'
Inventory	-26,985	3,918
Deposits	-3,537	-10,000
Other current assets	-10,494	7,905
Accounts payable and accrued expenses	99,947	117,315
Other current liabilities	0	2,000
Net cash used in operating activities	-401,849	-233,954
Cash flows from investing activities	'	'
Purchase of equipment	-18,335	0
Net cash used in investing activities	-18,335	0
Cash flows from financing activities	'	'
Proceeds from short-term advance	0	5,000
Advances from (to) affiliate, net	148,458	5,316
Proceeds from loan from affiliate	-82,448	-11,479
Repayment of loan from affiliate	0	119,000
Proceeds from issuance of convertible debenture	-1,000	0
Proceeds from issuance of common stock	538,163	0
Net cash provided by financing activities	603,173	117,837
Net change in cash and cash equivalents	182,989	-16,117
Cash and cash equivalents, beginning balance	4,891	120,697
Cash and cash equivalents, ending balance	187,880	4,580
Supplemental disclosure of cash flow information	'	'
Income taxes paid	0	0
Interest paid	0	0
Non-cash transactions affecting Operating, Investing and Financing activities	'	'
Issued notes payable for common stock buyback	79,667	0
Issuance of common stock for convertible notes converted	$447,325	$0

1_Nature_of_Operations_and_Bas

1. Nature of Operations and Basis of Presentation	9 Months Ended
1. Nature of Operations and Basis of Presentation	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
1. Nature of Operations and Basis of Presentation	'
	1. Nature of Operations and Basis of Presentation

	Nature of Operations

	Technology Applications International Corporation (formerly Raj Ventures, Inc.) (“Technology”) was incorporated on October 14, 2009 under the laws of Florida. Renuell Int’l, Inc. and NueEarth, Inc., Technology’s wholly owned subsidiaries and Technology, collectively, are referred to here-in as the “Company.” The Company is engaged in developing market entry technology products and services into early and mainstream technology products and services. Through our subsidiaries, we are focused on developing and manufacturing a line of technologically advanced skin care products and providing environmental management solutions that use electron particle accelerator technology.

	Principles of Consolidation

	The unaudited consolidated financial statements include the accounts of Technology Applications International Corporation and its wholly owned subsidiaries, Renuell Int’l, Inc. and NueEarth, Inc. All significant inter-company accounts and transactions have been eliminated in consolidation.

	Basis of Presentation and Going Concern Considerations

	The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2014.

	For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

	The accompanying financial statements have been presented on the basis that it is a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs. The Company’s ability to continue as a going concern is highly dependent upon management’s ability to increase near-term operating cash flows and obtain additional working capital through the issuance of debt and or equity. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

	These consolidated financial statements present the financial condition, and results of operations and cash flows of the operating companies.

	Business Risk

	Since its inception, the Company has been dependent upon the receipt of capital investment to fund its operating activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plans will be successfully executed. The Company’s ability to execute its business plans is dependent on its ability to obtain additional debt and equity financing and achieving a profitable level of operations. There can be no assurance that sufficient financing will be obtained or that we will achieve a profitable level of operations.

	Basic and Diluted Net Loss per Share

	The Company computes loss per share in accordance with “ASC-260”, “Earnings per Share” which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. The Company has potential dilutive instruments during the current three month period as there is net income; therefore there is potentially a dilutive share amount of 106,245,144. The Company does not have potential dilutive instruments during the nine month period and comparable periods as there are net losses, and accordingly basic loss and diluted loss per share are the same.

	Recent Accounting Pronouncements

	On June 10, 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-10 (ASU 2014-10), Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. ASU 2014-10 eliminates the requirement to present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclosure the risks and uncertainties related to their activities. ASU 2014-10 also eliminates an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The presentation and disclosure requirements in Topic 915 will no longer be required for interim and annual reporting periods beginning after December 15, 2014, and the revised consolidation standards will take effect in annual periods beginning after December 15, 2015. Early adoption is permitted. The Company adopted the provisions of ASU 2014-10 effective for its financial statements for the interim period ended September 30, 2014. The adoption of ASU 2014-10 did not have any effect on the Company’s financial statement presentation or disclosures.

	Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

2_Inventories

2. Inventories	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
2. Inventories	'
	2. Inventories

	Inventories are stated at the lower of cost or market value. The Company reduces the value of its inventories to market value when the value is believed to be less than the cost of the item.

		September	December
		30, 2014	31, 2013

	Raw materials	$ -	$ -
	Work-in-process	-	-
	Finished goods	97,847	70,862

	Total Inventories	$97,847	$70,862


	No reserves for inventory have been deemed necessary at September 30, 2014.

3_Machinery_and_Equipment

3. Machinery and Equipment	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
3. Machinery and Equipment	'
	3. Machinery and Equipment

	Machinery and equipment are recorded at cost. Expenditures for maintenance and repairs are charged to earnings as incurred whereas additions, renewals and betterments are capitalized. When machinery and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of machinery and equipment is provided using the straight-line method over the assets estimated useful lives of approximately 5 to 7 years. Leasehold improvements, if any, are amortized on a straight-line basis over the term of the lease or the estimated useful lives, whichever is shorter.

	Machinery and equipment, as of September 30, 2014 and December 31, 2013, consisted of the following:

		Estimated Useful Lives	September	December
			30, 2014	31, 2013

	Computer Equipment	3 Years	$ 5,980	$ 4,162
	Machinery and equipment	5 Years	13,418	13,418
	Furniture and fixtures	7 Years	30,590	14,073
	Accumulated depreciation		-16,247	-12,282

			$ 33,741	$ 19,371


	Depreciation expense for the nine month periods ended September, 2014 and 2013 were $3,964 and $2,979, respectively. Depreciation expense for the three month periods ended September 30, 2014 and 2013 were $1,499 and $993, respectively.

4_Convertible_Debenture

4. Convertible Debenture	9 Months Ended
4. Convertible Debenture	Sep. 30, 2014
Notes to Financial Statements	'
4. Convertible Debenture	'
	4. Convertible Debenture

	During December 2011, the Company received $100,000 as a deposit for entering into a distribution agreement. On March 22, 2012, the Company converted the $100,000 deposit into a convertible debenture. The convertible debenture bears interest at a rate of five-percent (5%) per annum and was payable March 21, 2014. At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share. In addition to the common stock, the Holder received warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share. These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise. In December 2013, the Noteholder elected to convert $25,000 into 50,000 shares of the Company’s Common Stock at $0.50 per share. In February 2014, the Noteholder elected to convert $84,143 (including accrued interest of $9,143) into 168,285 shares of the Company’s Common Stock at $0.50 per share. The Company issued 218,285 warrants to purchase 218,285 shares of common stock exercisable at $1.00 per share. As of September 30, 2014, all of the 218,285 warrants are expired.

	On September 25, 2012, the Company issued a $100,000 convertible debenture. The convertible debenture bears interest at a rate of five-percent (5%) per annum and was payable September 20, 2013. At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share. In addition to the common stock, the Holder received warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share. These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise. This convertible debenture extended 360 days on September 21, 2013. In December 2013, the Noteholder elected to convert $25,000 into 50,000 shares of the Company’s Common Stock at $0.50 per share. In February 2014, the Noteholder elected to convert $88,273 (including accrued interest of $13,273) into 176,515 shares of the Company’s Common Stock at $0.50 per share. The Company issued 226,515 warrants to purchase 226,515 shares of common stock exercisable at $1.00 per share. As of September 30, 2014, all of the 226,515 warrants are expired.

	On April 3, May 23, May 31, June 10, July 29, August 14, and September 25, 2013, the Company issued a $5,000, $10,000, $10,000, $25,000, $4,000, $50,000 and $20,000 convertible debentures, respectively. The convertible debentures bear interest at a rate of ten-percent (10%) per annum and are payable March 29, May 18, May 26, June 5, July 24, August 9, and September 20, 2014, respectively. At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share. In addition to the common stock, the Holder shall receive warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share. These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise. In February 2014, the Noteholder elected to convert $110,866 (including accrued interest of $6,866) into 220,785 shares of the Company’s Common Stock at $0.50 per share. The Company issued 220,785 warrants to purchase 220,785 shares of common stock exercisable at $1.00 per share. In April 2014, the Noteholder elected to convert $21,534 (including accrued interest of $1,534) into 41,534 shares of the Company’s Common Stock at $0.50 per share. The Company issued 41,534 warrants to purchase 41,534 shares of common stock exercisable at $1.00 per share. As of September 30, 2014, all of the 262,319 warrants are expired.

	On August 28, 2014, the Company entered into an unsecured promissory note with RAJ Ventures Funding Group, Inc., in the amount of $15,000. This note accrues interest at 6% per annum, is due on demand and contains customary events of default.

	The Compound derivative comprises certain derivative features embedded in the host convertible debenture contracts including the conversion feature and warrants both of which contain anti-dilution protections. These instruments were combined into one compound derivative and bifurcated from the host instrument at fair value. The Company applied the Black-Scholes Merton valuation technique to fair value these derivatives because this technique embodies all of the assumptions necessary to fair value these compound derivative instruments.

	Since the derivative financial instruments are required to be recorded, both initially, and subsequently, at fair value, there were insufficient proceeds to allocate any amount to the convertible debentures and, accordingly, it has no carrying value on the date of inception. Additionally, proceeds were insufficient to record the fair values of the derivative financial instruments, resulting in initial interest expense of $197,452. It should be noted that the derivative instruments will be adjusted to fair value at each reporting date. As the Company does not have historical volatility data for its own stock, the expected volatility was based upon the Company’s peer group in the industry in which it does business. Fair values are highly influenced by the trading stock price and volatility of the peer group, changes in our credit risk and market interest rates. The company amortizes the discount on the convertible debentures resulting from the initial allocation over the term of the convertible debt instruments using the effective method. Amortization expense arising from this method for nine months and the years ended September 30, 2014 and December 31, 2013 amounted to $75,902 and $182,197 which have been included as a component of interest expense. For the nine months ended September 30, 2014, gain on derivative valuation was $565,167 (For the year ended December 31, 2013, gain on the derivative valuation was $64,232)

5_Capital_Stock

5. Capital Stock	9 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
5. Capital Stock	'
	5. Capital Stock

	In February 2014, the Company issued 565,615 shares of its common stock at $0.50 for conversion of convertible debenture of $254,000 and $28,282 of accrued interest.

	In March 2014, the Company issued 601,000 shares of its common stock at $0.50 through a private placement for total cash consideration of $300,500. Also, Company issued 601,000 warrants to purchase to purchase 601,000 shares of common stock exercisable at $1.00 per share.

	On April 3, 2014, the Company entered stock subscription agreement of 5,000 shares at $1.00 per share with 5,000 warrants to purchase 5,000 shares of common stock with an exercise price of $2.00 per share. These warrants expire 180 days after stock issuance date.

	On April 16, 2014, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 20,000 warrants to purchase 20,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 180 days after stock issuance date.

	On July 7, and July 31, 2014, the Company entered stock subscription agreements of 50,000 shares and 20,000 shares at $1.00 per share with 50,000 and 20,000 warrants to purchase 50,000 and 20,000 shares of common stock with an exercise price of $2.00 per share. These warrants expire 360 days after stock issuance date.

	On August 22, 2014, the Company entered a stock subscription agreement of 99,963 shares at $1.00 per share with 99,963 warrants to purchase 99,963 shares of common stock with an exercise price of $2.00 per share. These warrants expire 1 year from the date the restricted common shares become free trading.

	On August 28, 2014, the Board authorized the Company to exchange or repurchase 68,666,619 shares of common stock in privately negotiated transactions with three shareholders, including the current CEO of the Company. As a result of the exchange or repurchase the Company’s total shares issued and outstanding will be reduced to Fifty Million (50,118,493) shares of common stock. The repurchase was made pursuant to a privately negotiated stock repurchase agreement. The per share repurchase price for the shares repurchased was determined through arms-length negotiations with the private investors. The exchange of shares was consummated at the price that the shares were issued for originally. The repurchase price was paid through cash on hand from the Company’s available surplus and through the issuance of unsecured promissory notes that accrue simple interest at 6% per annum. Other than this private transaction as described in this report, our board of directors has not authorized any stock repurchase program or plan, and we have no current plans to effect any open-market purchases of our common stock or other repurchases of our common stock.

	On September 9, 2014, a Warrant holder exercised 34,000 warrants to purchase 34,000 restricted common shares at a price of $1.00 per share.

	Due to a ratchet provision, the warrants issued during the year were accounted for as a derivative and fair valued using the Black Scholes valuation model. The initial valuation was $525,603, which was immediately expensed as derivative expense.

	Stock Purchase Warrants

	In conjunction with the Private Placement Memorandum dated February 13, 2013, the Company is offering up to 3,000,000 units. Each unit consists of 1 share of common stock priced at $1.00 and one Class A Warrant to purchase 1 share of common stock with an exercise price of $1.50 per share. These warrants expire on the earlier of (i) 180 days after the common stock commences quotation on the OTC Bulletin Board or (ii) one year after the date of issuance. No issuances have been sold from this offering as of December 31, 2013.

	In December 2013, the Noteholder elected to convert $50,000 into 100,000 shares of the Company’s Common Stock at $0.50 per share. The Company issued 100,000 warrants to purchase 100,000 shares of common stock exercisable at $1.00 per share. The warrants were expired in September 2014.

	In February and April 2014, the Noteholder elected to convert $304,049 (including accrued interest of $30,049) into 607,119 shares of the Company’s Common Stock at $0.50 per share. The Company issued 607,119 warrants to purchase 607,119 shares of common stock exercisable at $1.00 per share. The warrants were expired in September 2014.

	In March 2014, the Company issued 601,000 shares of its common stock at $0.50 through a private placement for total cash consideration of $300,500. Also, the Company issued 601,000 warrants to purchase 601,000 shares of common stock exercisable at $1.00 per share. 34,000 warrants were exercised in September 2014 and 567,000 warrants were expired in September 2014.

	On April 3, 2014, the Company entered stock subscription agreement of 5,000 shares at $1.00 per share with 5,000 warrants to purchase 5,000 shares of common stock with an exercise price of $2.00 per share. These warrants expire 180 days after stock issuance date. The warrants were expired in September 2014.

	On April 16, 2014, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 20,000 warrants to purchase 20,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 180 days after stock issuance date. As of September 30, 2014, 20,000 warrants are not exercised or expired.

	On July 7, and July 31, 2014, the Company entered stock subscription agreements of 50,000 shares and 20,000 shares at $1.00 per share with 50,000 and 20,000 warrants to purchase 50,000 and 20,000 shares of common stock with an exercise price of $2.00 per share. These warrants expire 360 days after stock issuance date.

	On August 22, 2014, the Company entered stock subscription agreement of 99,963shares at $1.00 per share with 99,963 warrants to purchase 99,963 shares of common stock with an exercise price of $2.00 per share. These warrants expire 1 year from the date the restricted common shares become free trading.

	On September 9, 2014, a Warrant holder exercised 34,000 warrants to purchase 34,000 restricted common shares at a price of $1.00 per share.

	The following table summarizes all warrant activity for the periods ended September 30, 2014:

		Shares		Weighted-Average Exercise Price Per Share
	Exercisable at December 31, 2013	100,000		1
	Granted	1,403,112		1.12
	Exercised	(34,000	)	1
	Expired	(1,237,615	)	1

	Exercisable at September 30, 2014	231,497		1.6

6_Fair_Value_Measurements

6. Fair Value Measurements	9 Months Ended
6. Fair Value Measurements	Sep. 30, 2014
Notes to Financial Statements	'
6. Fair Value Measurements	'
	6. Fair Value Measurements

	On a recurring basis, we measure certain financial assets and liabilities based upon the fair value hierarchy. The following table presents information about the Company’s liabilities measured at fair value as of September 30, 2014 and December 31, 2013:

		Level 1	Level 2	Level 3	Fair Value at
		Level 1	Level 2	Level 3	30-Sep-14
	Liabilities
	Derivative Liability	-	-	$ 148,285	$ 148,285


		Level 1	Level 2	Level 3	Fair Value at
		Level 1	Level 2	Level 3	31-Dec-13
	Liabilities
	Derivative Liability	-	-	$ 349,940	$ 349,940


	The fair value changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), relate solely to the derivative liability as follows:

	Balance as of December 31, 2012	$ 276,000
	Derivative liability recorded	266,912
	Adjustment due to conversion	-31,080
	Fair value adjustment	-161892
	Balance at December 31, 2013	349,940
	Adjustment due to conversion	-143,391
	Adjustment due to exercise warrant	-18,700
	New warrant issued with stock	525,603
	Fair value adjustment	-565,167
	Balance at September 30, 2014	$ 148,285

7_Related_Parties

7. Related Parties	9 Months Ended
7. Related Parties	Sep. 30, 2014
Related Party Transactions [Abstract]	'
7. Related Parties	'
	7. Related Parties

	An affiliate of the Company, an entity owned by the Company’s president, has been funding operations of the Company by making payments directly to third parties or advancing monies to the Company. These amounts bear no interest and are payable on demand. Amounts due to the affiliate at September 30, 2014 and December 31, 2013 are approximately $303,000 and $237,000, respectively.

	During September 2012, the Company borrowed $125,000 from an affiliate. During the September 2014, the Company borrowed $64,667 from an affiliate. The loans bear interest at 6-10% per annum and are unsecured and payable upon demand. The outstanding balance at September 30, 2014 and December 31, 2013 is $142,068 and $77,401, respectively.

	On August 28, 2014, the Board authorized the Company to exchange or repurchase 68,666,619 shares of common stock in privately negotiated transactions with three shareholders, including the current CEO of the Company. As a result of the exchange or repurchase the Company’s total shares issued and outstanding will be reduced to Fifty Million One Hundred Eighteen Thousand Four Hundred Ninety Three (50,118,493) shares of common stock. The repurchase was made pursuant to a privately negotiated stock repurchase agreement. The per share repurchase price for the shares repurchased was determined through arms-length negotiations with the private investors. The exchange of shares was consummated at the price that the shares were issued for originally. The repurchase price was paid through cash on hand from the Company’s available surplus and through the issuance of unsecured promissory notes that accrue simple interest at 6% per annum. Other than this private transaction as described in this report, our board of directors has not authorized any stock repurchase program or plan, and we have no current plans to effect any open-market purchases of our common stock or other repurchases of our common stock.

	On August 28, 2014, the Company entered into an unsecured promissory note (the “Note”) with RAJ Ventures Funding, Inc., (the “Lender”) in the amount of $15,000 that accrues 6% simple interest and is due on demand. The Note was entered into in exchange for the purchase of the Lenders 1,000,000 shares in the Company.

8_License_Agreement

8. License Agreement	9 Months Ended
8. License Agreement	Sep. 30, 2014
Notes to Financial Statements	'
8. License Agreement	'
	8. License Agreement

	On July 25, 2014, Technology Applications International Corporation and its wholly-owned subsidiary Renuell Int’l, Inc., Florida corporations (the “Company”) entered into an exclusive License Agreement (the “License Agreement”) by and between the National Aeronautics and Space Administration, an agency of the United States (“N.A.S.A.”) for the use of U.S. Patent No.’s 6,485,963 B1, an invention entitled “Growth Stimulation Of Biological Cells and Tissue By Electromagnetic Fields and Uses Thereof” which was filed on June 2, 2000, and U.S. Patent No. 6,673,597 B2, for an invention entitled “Growth Stimulation of Biological Cells and Tissue By Electromagnetic Fields and Uses Thereof: which was filed on February 28, 2001 (the “Patents”). We currently use the Patents process to develop our anti-aging skin creams and shampoos. The License Agreement permits the Company to use the Patents as well as the name N.A.S.A., with its products, as per the terms of the License Agreement.

	In consideration of the grant of the License Agreement, the Company will pay a 3% royalty to N.A.S.A. on the gross sales of any royalty-base products. The License agreement further requires the Company to remit to N.A.S.A. a non-refundable license fee in the amount of Fifteen Thousand Dollars ($15,000) upon the execution of the License Agreement and then another Fifteen Thousand Dollars ($15,000) is due six months after the license commencement date. The Company also agrees to pay N.A.S.A. a minimum royalty of Fifteen Thousand Dollars ($15,000), at the end of each accounting period (“Accounting Period”). The Accounting Period shall begin at the end of the second Accounting period of the License Agreement and each Accounting period thereafter.

	The License Agreement requires that the Company achieve a practical application of the Patent within eighteen (18) months from the commencement date of the License Agreement. In accordance with the appendix to the License Agreement; wherein it states that by August 2014, the Company shall have tested the product to meet federal, state and international regulations of its skin cream products, by October 2014, the Company shall have packaged and filled five products and by December 2014, the Company shall have Domestic and International distribution of five products. Once a practical application is achieved the term of the agreement shall be equal to the unexpired term of the last patent to be in effect of the patent(s) encompassed under the Patents. The Company further agrees that any products using the Patents process shall be substantially manufactured in the United States. As of the Date of this filing all milestones associated with the License Agreement have been completed on time and to the satisfaction of the License Agreement Parties.

9_Commitment

9. Commitment	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
9. Commitment	'
	9. Commitment

	September 10, 2014, the Company signed a lease agreement for office used. Lease term is twenty-six months from October 1, 2014. Rental is $39,555 for twelve months.

	Year	Commitment Payment
	Remainder of 2014	$3,297
	2015	$39,555
	2016	$36,258

10_Subsequent_Events

10. Subsequent Events	9 Months Ended
10. Subsequent Events	Sep. 30, 2014
Subsequent Events [Abstract]	'
10. Subsequent Events	'
	10. Subsequent Events

	On October 1, 2014, the Company signed an agreement with Strawberry Bullett, LLC, a New York based advertising agency that will assist the Company’s wholly-owned subsidiary Rejuvel, with market research, and branding services for its facial cream, as well as assisting with creating a marketing and advertising campaign for our subsidiary.

	On or about October 9, 2014, The Company completed a clinical study to test the efficacy of their products at Essex Testing Clinic in Verona, New Jersey. Team members on The Essex Testing Clinic staff included doctors, nurses, clinical study, recruitment professionals, quality assurance and trained evaluators and a large network of consulting physicians, all possessing considerable experience in clinical investigation. Team personnel evaluated facial imperfections of each subject and took scientific measurements to determine the firmness and elasticity of the skin to detect change.

	After 6 weeks of product use, 32 subjects responded with the following:


	• 100% – Smoother and softer skin.
	• 100% – Facial skin had an improved texture.
	• 100% – Product regimen was gentle and non-irritating.
	• 84.4% – Appearance of fine lines on face is less noticeable.
	• 78.1% – Appearance of wrinkles on face is less noticeable.
	• 81.3% – Improvement in the firmness/elasticity of skin.
	• 75.0% – Reduction in the appearance of dark, under the eye circles.
	• 84.4% – Skin appeared renewed and discolorations were reduced.
	• 87.5% – Moisture content in skin had increased.
	• 90.6% – Skin appears brighter and more radiant.
	• 90.6% – Skin appears healthier.
	• 93.8% – Skin appears refreshed.
	• 87.5% – Overall appearance was improved.

	Scientific Measurements results after 6 weeks of use are as follows:

	• 78% of subjects Fine Lines/ Wrinkles were significantly reduced
	• 88% of subjects Under Eye Discoloration significantly improved
	• 78% of subjects Firmness/ Elasticity significantly improved
	• 97% of subjects Skin Moisture significantly improved

	The conclusion of this clinical study fulfills the requirements to be able to broadcast on the major home shopping channels. Our next step is to voluntarily submit our testing claims to the Federal Drug Administration (FDA).

	On or about October 13, 2014, the Company entered into an distribution agreement (“Distribution Agreement”) with Olgun Emirzade, who is a Director of Meditem Cyprus Limited (“Meditem”); thereby, naming Northern Cyprus as a non-exclusive territory for Meditem. The terms of the Distribution Agreement, expects that Meditem will sell a minimum of 200 units of skin cream a month for the first year, allows for Meditem to receive a finder’s fee for each 1.7oz bottle purchased by any newly referred distributor in the Republic of Cyprus. The Distribution Agreement is for a period of one year and then the two parties will evaluate the progress and the Distribution Agreement can be renewed for an additional five one year periods. The Distribution Agreement also calls for a quota to be established after the first year of the Distribution Agreement that the more territories and exclusivity to territories may be adjusted in further negotiations.

	Pursuant to Accounting Standards Codification 855-10, the Company has evaluated all events or transactions that have occurred from November 12, 2014 through the filing with the SEC.

1_Nature_of_Operations_and_Bas1

1. Nature of Operations and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Nature of Operations	'
	Nature of Operations

	Technology Applications International Corporation (formerly Raj Ventures, Inc.) (“Technology”) was incorporated on October 14, 2009 under the laws of Florida. Renuell Int’l, Inc. and NueEarth, Inc., Technology’s wholly owned subsidiaries and Technology, collectively, are referred to here-in as the “Company.” The Company is engaged in developing market entry technology products and services into early and mainstream technology products and services. Through our subsidiaries, we are focused on developing and manufacturing a line of technologically advanced skin care products and providing environmental management solutions that use electron particle accelerator technology.

Principles of Consolidation	'
	Principles of Consolidation

	The unaudited consolidated financial statements include the accounts of Technology Applications International Corporation and its wholly owned subsidiaries, Renuell Int’l, Inc. and NueEarth, Inc. All significant inter-company accounts and transactions have been eliminated in consolidation.

Basis of Presentation and Going Concern Considerations	'
	Basis of Presentation and Going Concern Considerations

	The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2014.

	For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

	The accompanying financial statements have been presented on the basis that it is a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs. The Company’s ability to continue as a going concern is highly dependent upon management’s ability to increase near-term operating cash flows and obtain additional working capital through the issuance of debt and or equity. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

	These consolidated financial statements present the financial condition, and results of operations and cash flows of the operating companies.

Business Risk	'
	Business Risk

	Since its inception, the Company has been dependent upon the receipt of capital investment to fund its operating activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plans will be successfully executed. The Company’s ability to execute its business plans is dependent on its ability to obtain additional debt and equity financing and achieving a profitable level of operations. There can be no assurance that sufficient financing will be obtained or that we will achieve a profitable level of operations.

Basic and Diluted Net Loss per Share	'
	Basic and Diluted Net Loss per Share

	The Company computes loss per share in accordance with “ASC-260”, “Earnings per Share” which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. The Company has potential dilutive instruments during the current three month period as there is net income; therefore there is potentially a dilutive share amount of 106,245,144. The Company does not have potential dilutive instruments during the nine month period and comparable periods as there are net losses, and accordingly basic loss and diluted loss per share are the same.

Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements

	On June 10, 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-10 (ASU 2014-10), Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. ASU 2014-10 eliminates the requirement to present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclosure the risks and uncertainties related to their activities. ASU 2014-10 also eliminates an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The presentation and disclosure requirements in Topic 915 will no longer be required for interim and annual reporting periods beginning after December 15, 2014, and the revised consolidation standards will take effect in annual periods beginning after December 15, 2015. Early adoption is permitted. The Company adopted the provisions of ASU 2014-10 effective for its financial statements for the interim period ended September 30, 2014. The adoption of ASU 2014-10 did not have any effect on the Company’s financial statement presentation or disclosures.

	Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

2_Inventories_Tables

2. Inventories (Tables)	9 Months Ended
2. Inventories (Tables)	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
		September	December
		30, 2014	31, 2013

	Raw materials	$ -	$ -
	Work-in-process	-	-
	Finished goods	97,847	70,862

	Total Inventories	$97,847	$70,862

3_Machinery_and_Equipment_Tabl

3. Machinery and Equipment (Tables)	9 Months Ended
3. Machinery and Equipment (Tables)	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Machinery and equipment	'
		Estimated Useful Lives	September	December
		Estimated Useful Lives	30, 2014	31, 2013

	Computer Equipment	3 Years	$ 5,980	$ 4,162
	Machinery and equipment	5 Years	13,418	13,418
	Furniture and fixtures	7 Years	30,590	14,073
	Accumulated depreciation		-16,247	-12,282

			$ 33,741	$ 19,371

5_Capital_Stock_Tables

5. Capital Stock (Tables)	9 Months Ended
5. Capital Stock (Tables)	Sep. 30, 2014
Notes to Financial Statements	'
Warrant Activity	'
		Shares		Weighted-Average Exercise Price Per Share
	Exercisable at December 31, 2013	100,000		1
	Granted	1,403,112		1.12
	Exercised	(34,000	)	1
	Expired	(1,237,615	)	1

	Exercisable at September 30, 2014	231,497		1.6

6_Fair_Value_Measurements_Tabl

6. Fair Value Measurements (Tables)	9 Months Ended
6. Fair Value Measurements (Tables)	Sep. 30, 2014
Notes to Financial Statements	'
Derivative Liabilities	'

		Level 1	Level 2	Level 3	Fair Value at
		Level 1	Level 2	Level 3	30-Sep-14
	Liabilities
	Derivative Liability	-	-	$148,285	$148,285

		Level 1	Level 2	Level 3	Fair Value at
		Level 1	Level 2	Level 3	31-Dec-13
	Liabilities
	Derivative Liability	-	-	$349,940	$349,940

Derivative Liability Fair Value Adjustment	'
	Balance as of December 31, 2012	$ 276,000
	Derivative liability recorded	266,912
	Adjustment due to conversion	-31,080
	Fair value adjustment	-161892
	Balance at December 31, 2013	349,940
	Adjustment due to conversion	-143,391
	Adjustment due to exercise warrant	-18,700
	New warrant issued with stock	525,603
	Fair value adjustment	-565,167
	Balance at September 30, 2014	$ 148,285

9_Commitment_Tables

9. Commitment (Tables)	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Office Lease	'
	Year	Commitment Payment
	Remainder of 2014	$3,297
	2015	$39,555
	2016	$36,258

1_Nature_of_Operations_and_Bas2

1. Nature of Operations and Basis of Presentation (Details)	3 Months Ended		9 Months Ended
1. Nature of Operations and Basis of Presentation (Details)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Accounting Policies [Abstract]	'	'	'	'
Diluted	106,245,144	117,248,000	110,001,487	117,248,000

2_Inventories_Details

2. Inventories (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Inventory Disclosure [Abstract]	'	'
Raw materials	$0	$0
Work-in-process	0	0
Finished goods	97,847	70,862
Total Inventories	$97,847	$70,862

3_Machinery_and_Equipment_Deta

3. Machinery and Equipment (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
3. Machinery and Equipment (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Computer Equipment	Machinery and Equipment	Furniture and Fixtures
Computer Equipment	$5,980	$4,162	'	'	'
Machinery and equipment	13,418	13,418	'	'	'
Furniture and fixtures	30,590	14,073	'	'	'
Accumulated depreciation	-16,247	-12,282	'	'	'
Machinery and equipment, net	$33,741	$19,371	'	'	'
Estimated useful lives	'	'	'3 years	'5 years	'7 years

3_Machinery_and_Equipment_Deta1

3. Machinery and Equipment (Details Narrative) (USD $)	3 Months Ended		9 Months Ended
3. Machinery and Equipment (Details Narrative) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'	'	'	'
Depreciation expense	$1,499	$993	$3,964	$2,979

4_Convertible_Debenture_Detail

4. Convertible Debenture (Details) (USD $)	9 Months Ended		12 Months Ended
4. Convertible Debenture (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Notes to Financial Statements	'	'	'
Compound derivative	$525,603	$0	'
Interest expense	'	'	$197,452

4_Convertible_Debenture_Detail1

4. Convertible Debenture (Details Narrative) (USD $)

1 Months Ended

9 Months Ended

12 Months Ended

Apr. 30, 2014

Feb. 28, 2014

Dec. 31, 2013

Dec. 31, 2011

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Aug. 28, 2014

Apr. 16, 2014

Apr. 03, 2014

Sep. 25, 2013

Aug. 14, 2013

Jul. 29, 2013

Jun. 10, 2013

31-May-13

23-May-13

Apr. 03, 2013

Sep. 25, 2012

Mar. 22, 2012

Notes to Financial Statements

Deposit on distribution agreeement

$100,000

Deposit converted into convertible debenture

100,000

Convertible debenture issued

20,000

50,000

4,000

25,000

10,000

5,000

100,000

Interest rate of convertible debenture, per annum

10.00%

0.00%

5.00%

Maturity date of convertible debenture

'1 year

Debt conversion to common stock rate

$0.50

Number of warrants offered per share issued from converted debt

Warrants exercisable for common stock, price per share

Expiration of warrants, years

'1 year

Expiration of warrants, days after common stock is quoted on OTCBB

'180 days

Initial Interest expense

197,452

Amortization expense

75,902

214,963

182,197

Gain (loss) on derivative valuation

565,167

-161,892

Amount of debt converted from debentures

254,000

Shares of common stock issued from conversion of debentures

485,000

Amount of convertible debentures still outstanding

19,999

Debt discount on convertible debt

9,611

Net convertible debt

10,388

Amount of debt converted from 2013 debentures

20,767

110,866

Shares of common stock issued from conversion of 2013 debentures

41,543

220,785

Price per share of common stock converted from 2013 debentures

$0.50

Warrants issued for 2013 debentures

41,534

220,785

Exercise price of warrants issued for 2013 debentures

Expiration period of warrants issued for 2013 debentures

21-Sep-14

Warrants outstanding of the 2013 debenture warrants

Amount of 2013 convertible debentures still outstanding

21,025

Amount of debt converted from December 2011 debenture

84,143

25,000

Shares of common stock issued from conversion of December 2011 debenture

168,285

50,000

Price per share of common stock converted from December 2011 debenture

$0.50

Amount of debt converted from September 2012 debenture

88,273

25,000

Shares of common stock issued from conversion of September 2012 debenture

176,515

50,000

Price per share of common stock converted from September 2012 debenture

$0.50

Warrants issued for December 2011 debenture

218,285

Exercise price of warrants issued for December 2011 debenture

Expiration date of warrants issued for December 2011 debenture

21-Sep-14

Warrants outstanding of the December 2011 debenture warrants

Warrants issued for September 2012 debenture

226,515

Exercise price of warrants issued for September 2012 debenture

Expiration date of warrants issued for September 2012 debenture

21-Sep-14

Warrants outstanding of the September 2012 debenture warrants

Unsecured promissory note due RAJ Ventures

$15,000

Interest rate of promissory note due RAJ Ventures

6.00%

5_Capital_Stock_Details

5. Capital Stock (Details) (USD $)	1 Months Ended	24 Months Ended			9 Months Ended
	Mar. 31, 2014	Dec. 31, 2012	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
	Mar. 31, 2014	Dec. 31, 2012	Exercisable	Exercisable	Granted	Exercised	Expired
Number of Warrant Shares, instant	'	'	231,497	100,000	'	'	'
Number of Warrant Shares, duration	601,000	1,030,000	'	'	1,403,112	-34,000	-1,237,615
Weighted Average Exercise Price, instant	'	'	$1.60	$1	'	'	'
Weighted Average Exercise Price, duration	'	'	'	'	$1.12	'	'

5_Capital_Stock_Details_Narrat

5. Capital Stock (Details Narrative) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

24 Months Ended

Apr. 30, 2014

Mar. 31, 2014

Feb. 28, 2014

Sep. 30, 2014

Apr. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Aug. 28, 2014

Aug. 22, 2014

Jul. 31, 2014

Jul. 07, 2014

Apr. 16, 2014

Apr. 03, 2014

Sep. 25, 2013

Aug. 14, 2013

Jul. 29, 2013

Jun. 10, 2013

31-May-13

23-May-13

Apr. 03, 2013

Feb. 13, 2013

Sep. 25, 2012

Mar. 22, 2012

Units

Notes to Financial Statements

Common stock issued for cash, shares

99,963

20,000

50,000

20,000

5,000

Common stock issued for cash, value

$99,963

$20,000

$50,000

$10,000

$5,000

Common stock issued for cash, shares, duration

601,000

Common stock issued for cash, value, duration

300,500

Private placement units offered

3,000,000

Shares per unit

Common stock price per share

$0.50

Warrants per unit

Class A Warrants, shares per warrant

Exercise price per share in warrant

$1.50

Expiration of warrants, years

'1 year

Expiration of warrants, days after common stock is quoted on OTCBB

'180 days

Number of untis sold in February 13, 2013 private offering

Number of warrant shares issued, shares

601,000

1,030,000

Common stock issued for debt, shares, duration

565,615

607,119

Common stock issued for debt, amount, duration

254,000

304,049

Common stock issued for debt, price per share

$0.50

Common stock issued for accrued interest on debt, amount, duration

28,282

Common stock issued for cash, price per share

$0.50

Warrants issued for debenture conversion

485,000

607,119

Exercise price of warrants issued for debenture conversion

Subscription receivable

66,500

Exercise price of warrants issued for stock purchase, duration

Warrant expiration period

'180 days

'1 year

Valuation of warrants issued

525,623

Warrants included in stock issuance

99,963

20,000

50,000

20,000

5,000

Shares underlying warrants in stock issuance

99,963

20,000

50,000

20,000

5,000

Exercise price of warrants in stock issuance

Warrants issued for March/April 2014 debenture

226,515

Exercise price of warrants issued for March/April 2014 debenture

Amount of debt converted from debentures

$254,000

Shares of common stock issued from conversion of debentures

485,000

Shares repurchased from shareholders and returned to treasury

68,666,619

Warrants exercised

34,000

Exercise price of warrants exercised

Shares issued from exercise of warrants

34,000

6_Derivative_Liabilities_Detai

6. Derivative Liabilities (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Dec. 31, 2013
6. Derivative Liabilities (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Level 1	Level 1	Level 2	Level 2	Level 3	Level 3	Fair Value	Fair Value
Derivative liability	$148,285	$349,940	$276,000	$0	$0	$0	$0	$148,285	$349,940	$148,285	$349,940

6_Derivative_Liability_Fair_Va

6. Derivative Liability Fair Value Adjustment (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Notes to Financial Statements	'	'	'
Derivative liability	$148,285	$349,940	$276,000
Derivative liability recorded	'	266,912	'
Fair value adjustment	565,167	-161,892	'
Adjustment due to conversion	-143,391	-31,080	'
Adjustment due to exercise warrant	-18,700	'	'
New warrant issued with stock	$525,603	'	'

7_Related_Parties_Details_Narr

7. Related Parties (Details Narrative) (USD $)	1 Months Ended
7. Related Parties (Details Narrative) (USD $)	Jun. 30, 2012	Sep. 30, 2014	Dec. 31, 2013
Related Party Transactions [Abstract]	'	'	'
Due to affiliates	'	$336,000	$237,000
Loan from affiliate	125,000	'	'
Interest rate on loan from affiliate	10.00%	'	'
Oustanding balance on loan from affiliate	'	$77,401	$77,401

8_License_Agreement_Details_Na

8. License Agreement (Details Narrative) (USD $)	3 Months Ended
	Sep. 30, 2014	Jul. 25, 2014
		Products
		Patents
Notes to Financial Statements	'	'
Royalty percent paid to NASA for use of two patent in exclusive License Agreement	'	3.00%
Number of patents included in exclusive License Agreement with NASA	'	2
Non-refundable license fee paid to NASA upon execution of License Agreement	'	$15,000
Second License Agreement fee due to NASA	'	15,000
Due date of second license fee due to NASA	'6 months	'
Minimum annual royalty due to NASA for License Agreement	'	$15,000
Required time period to reach practical application of patents with License Agreement	'18 months	'
Required number of products required to be filled, packaged, and have distribution by December 2014	'	5

9_Commitment_Details

9. Commitment (Details) (USD $)	3 Months Ended	12 Months Ended
9. Commitment (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]	'	'	'
Commitment Payment Due	$3,297	$36,258	$39,555

9_Commitment_Details_Narrative

9. Commitment (Details Narrative)	0 Months Ended
9. Commitment (Details Narrative)	Sep. 11, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Rental Lease commitment	'26 months

10_Subsequent_Events_Details_N

10. Subsequent Events (Details Narrative) (USD $)

0 Months Ended

1 Months Ended

9 Months Ended

Oct. 14, 2014

Feb. 28, 2014

Sep. 30, 2014

Aug. 28, 2014

Aug. 22, 2014

Jul. 31, 2014

Jul. 07, 2014

Apr. 16, 2014

Apr. 03, 2014

Sep. 25, 2013

Aug. 14, 2013

Jul. 29, 2013

Jun. 10, 2013

31-May-13

23-May-13

Apr. 03, 2013

Feb. 13, 2013

Sep. 25, 2012

Mar. 22, 2012

Distribution agreement with Olgun Emirzade

Skin cream units agreed to sell per month, minimum

200

Distibution Agreement duration

'1 year

Common stock issued for cash, shares

99,963

20,000

50,000

20,000

5,000

Common stock issued for cash, value

$99,963

$20,000

$50,000

$10,000

$5,000

Common stock issued for cash, price per share

$0.50

Warrants included in stock issuance

99,963

20,000

50,000

20,000

5,000

Shares underlying warrants in stock issuance

99,963

20,000

50,000

20,000

5,000

Exercise price of warrants in stock issuance

Warrants issued for March/April 2014 debenture

226,515

Exercise price of warrants issued for March/April 2014 debenture

Amount of debt converted from debentures

$254,000

Shares of common stock issued from conversion of debentures

485,000